At the time of writing, Syros Pharmaceuticals Inc. [SYRS] stock is trading at $2.53, up 19.91%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SYRS shares have gain 2.43% over the last week, with a monthly amount glided 17.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Syros Pharmaceuticals Inc. [NASDAQ: SYRS] stock has seen the most recent analyst activity on November 04, 2020, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $15 from $11. Previously, Alliance Global Partners started tracking the stock with Buy rating on September 22, 2020, and set its price target to $18. On January 17, 2020, downgrade downgraded it’s rating to Neutral. ROTH Capital upgraded its rating to Buy for this stock on November 05, 2018. In a note dated March 13, 2018, Wedbush reiterated an Outperform rating on this stock and boosted its target price from $11 to $13.
For the past year, the stock price of Syros Pharmaceuticals Inc. fluctuated between $1.43 and $8.17. Currently, Wall Street analysts expect the stock to reach $16.67 within the next 12 months. Syros Pharmaceuticals Inc. [NASDAQ: SYRS] shares were valued at $2.53 at the most recent close of the market. An investor can expect a potential return of 558.89% based on the average SYRS price forecast.
Analyzing the SYRS fundamentals
According to Syros Pharmaceuticals Inc. [NASDAQ:SYRS], the company’s sales were 4.15M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at -28.92%, Pretax Profit Margin comes in at -31.72%, and Net Profit Margin reading is -31.72%. To continue investigating profitability, this company’s Return on Assets is posted at -1.23, Equity is -8.53 and Total Capital is -1.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.12 points at the first support level, and at 1.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.86, and for the 2nd resistance point, it is at 3.18.
Ratios To Look Out For
It is important to note that Syros Pharmaceuticals Inc. [NASDAQ:SYRS] has a current ratio of 3.46. Also, the Quick Ratio is 3.46, while the Cash Ratio stands at 3.22. Considering the valuation of this stock, the price to sales ratio is 16.34.
Transactions by insiders
Recent insider trading involved Chee Conley, President & CEO, that happened on Sep 11 ’24 when 50000.0 shares were purchased. Chief Financial Officer, Haas Jason completed a deal on Sep 12 ’24 to buy 45344.0 shares. Meanwhile, President & CEO Chee Conley bought 50000.0 shares on Sep 10 ’24.
